More recently, biomarkers such as the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), immune-checkpoint genes, EMT markers, and cancer stem cells (CSCs) have emerged as important markers of CTCs with metastatic potential [222]. This evidence concerns the gene ESR1 and cancer.